Press Release / Health and Fitness / Overactive Bladder Treatment Market Size, Share, Outlook and Opportunity Analysis 2018 - 2026

Overactive Bladder Treatment Market Size, Share, Outlook and Opportunity Analysis 2018 - 2026

Overactive bladder is a common medical condition where there is sudden urge of urination. Overactive bladder is sometimes coupled with urine leakage, condition known as incontinence. Millions of people across the globe suffers from overactive bladder and it is more common in old age people.

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/2007

Urine leakage and frequent urination are the main symptoms of overactive bladder. The frequency of urination in the patient is around eight times a day. Moreover, frequent urination during sleep hours is common in such patients. Overactive bladder is commonly diagnosed by tests such as urine culture, bladder scan, cystoscopy or urodynamic testing.

Robust drug pipeline with drugs in phase II and phase III clinical trials, soon expected to be in the market, are expected to drive the overactive bladder treatment market growth. However, alternate therapies such as the neuromodulation therapy which includes sacral neuromodulation and percutaneous tibial nerve stimulation to deliver electric impulse to nerve, are expected to hinder the overactive bladder treatment market growth.

Overactive Bladder Treatment Market Dynamics

High prevalence of overactive bladder is expected to propel the overactive bladder treatment market growth over the forecast period. Moreover, increasing awareness about the importance of diagnosis and treatment of the disease is a key factor leading to increase in number of patients treated for overactive bladder.

Furthermore, increasing number of drug development programs for overactive bladder is expected to fuel the overactive bladder treatment market growth, by adding new drug in the market. Currently, generic drugs such as cholinergic receptor inhibitors are available for treatment of the condition. Therefore, development and approval of new drug entity with better drug profile is expected to boost the market growth.

Overactive Bladder Treatment Market - Taxonomy


On the basis of drug type, the overactive bladder treatment market is segmented into:

Anticholinergics
Oxybutynin
Darifenacin
Fesoterodine
Solifenacin
Tolterodine
Trospium
Mirabegron
Botox

On the basis of route of administration, the overactive bladder treatment market is segmented into:

Topical
Oral
Intravenous

On the basis of distribution channel, the overactive bladder treatment market is segmented into:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Overactive Bladder Treatment Market - Regional Analysis

The global overactive bladder treatment market is segmented into six regions that include, North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America overactive bladder treatment market holds dominant position amongst other regions, owing to high prevalence of overactive bladder in the region. For instance, according to the journal Current Bladder Dysfunction Reports, 2016 review, millions of people suffer from overactive bladder in the U.S. and estimates continuous increase in cost of overactive bladder management. However, increasing awareness about the disease in Asia Pacific regions is expected to boost the regional Asia Pacific overactive bladder treatment market growth in the region, over the forecast period at a fast rate.

Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/2007

Overactive Bladder Treatment Market – Competitive Analysis

Key players operating in the overactive bladder treatment market include, Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc. (subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., Pfizer Inc., Astellas Pharma Inc., Endo International PLC, and Invagen Pharmaceuticals Inc.

Key players operating in the market are focusing on leveraging their expertise to develop novel treatment therapies for the disease, to enhance their market share. For instance, in 2017, UroGen Pharma Ltd .a clinical-stage biopharmaceutical company in collaboration with Allergan Pharmaceuticals International Limited entered in phase II clinical trial for RTGel in combination with BOTOX, for overactive bladder treatment. RTGel is a hydrogel-based proprietary formulation of UroGen Pharma Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com